Market Overview
Hyper personalized medicine is an advanced healthcare approach that tailors medical treatment and preventive strategies to individual patients based on their unique biological, genetic, environmental and lifestyle factors. It goes beyond traditional medical practices by utilizing cutting-edge technologies like genomics, proteomics, metabolomics and bioinformatics to offer treatments that are highly specific to the molecular and cellular characteristics of each patient. This approach is revolutionizing healthcare by improving outcomes, reducing side effects and enabling preventive measures based on predictive insights.
The demand for hyper personalized medicine is rapidly expanding. For instance, according to the Personalized Medicine Coalition (PMC), With the approval of 17 new personalized medicines in 2021, personalized medicines, account for more than a quarter of the new drugs the agency has approved in, the past seven years. This figure represents a sharp recent increase. Just a decade ago, personalized medicines accounted for less than 10 percent of the new therapies approved each year. This market is set to transform healthcare delivery by integrating advanced technologies with precise, patient-centered care models, ensuring better outcomes and efficiency.
Executive Summary
Market Dynamics: Drivers & Restraints
Rising advancements in genomic technologies
Rising advancements in genomic technologies are significantly driving the growth of the hyper personalized medicine market and are expected to drive the market over the forecast period. Technologies like Next-Generation Sequencing (NGS) have drastically reduced the cost and time needed for genome sequencing. According to the J. Craig Venter Institute, the cost of sequencing a human genome has dropped from over USD 100 million in 2001 to less than USD 1,000 today and takes only a few hours, making personalized medicine more accessible to a broader population​.
Major market players are focussing on the development of hyper personalized medicine approaches, which further fueling the market growth. For instance, in March 2024, Nucleus Genomics, the next-generation genetic testing and analysis company, launched its DNA analysis product to bring the benefits of personalized medicine to everyone. Nucleus combined the power of whole-genome sequencing with innovative genomic analyses, ushering in a new era of personalized medicine for the public.
CRISPR gene-editing technology is enabling the development of personalized therapies by directly targeting the genetic causes of diseases. Companies are using CRISPR to explore treatments for genetic disorders such as sickle cell anemia and muscular dystrophy, offering highly personalized and potentially curative treatments​.
For instance, in May 2024, Researchers at Columbia University College of Dental Medicine developed an exosome-based platform, "safeEXO-Cas," that significantly enhances the delivery of CRISPR/Cas9 genome editing components to specific cells and tissues. The potential of this innovative platform is to revolutionize gene therapy and precision medicine.
Complexity of data integration
The complexity of data integration is expected to hamper the growth of the hyper personalized medicine market. This issue primarily arises from the integration of vast and varied datasets, which include genomic, proteomic, clinical and environmental data. These challenges impact the ability to efficiently develop personalized treatment plans, slowing the adoption of hyper personalized medicine.
Personalized medicine requires the integration of large-scale data from different sources like electronic health records (EHRs), genomic sequencing, medical imaging and real-time monitoring devices. These data types are often siloed across systems and lack standardization, making it difficult to draw comprehensive insights. For instance, genomic data might be stored in one system, while clinical data is in another, and patient health records are stored in yet another platform. This lack of uniformity complicates the creation of a cohesive, actionable profile for individual patients​.
Healthcare systems across different regions often use incompatible technologies, leading to poor interoperability between electronic health systems. For instance, a report by the American Health Information Management Association (AHIMA) indicates that 80% of healthcare organizations in the U.S. experience data integration issues, which directly affects the efficiency of personalized treatments​.
For more details on this report – Request for Sample
Segment Analysis
The global hyper personalized medicine market is segmented based on product type, technology, application, end-user and region.
Application:
The oncology segment is expected to dominate the hyper personalized medicine market share
The oncology segment is expected to dominate the global hyper personalized medicine market. Cancer is one of the most prevalent diseases worldwide. The increasing prevalence directly increases the demand for effective treatments, particularly in the face of diverse tumor types, this has accelerated the shift toward personalized oncology.
For instance, according to the National Institute of Health, cancer is among the leading causes of death worldwide. In 2022, there were almost 20 million new cases and 9.7 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million. Personalized approaches in oncology allow for targeting specific mutations in tumors, offering better outcomes and reducing side effects compared to traditional treatments.
The use of genomic profiling in oncology allows for identifying genetic mutations that drive cancer progression, enabling more accurate diagnoses and targeted treatments. Technologies like Next-Generation Sequencing (NGS) are extensively used to analyze tumor genomes. For instance, FoundationOne by Foundation Medicine offers comprehensive genomic profiling of solid tumors to identify actionable mutations, guiding the selection of targeted therapies​.
Geographical Analysis
North America is expected to hold a significant position in the hyper personalized medicine market share
North America is expected to hold the largest market share in the global hyper personalized medicine market. North America, particularly the United States is a global leader in biomedical research, accounting for approximately 60% of the world's total healthcare R&D spending. Significant funding is provided for the development of precision medicine technologies, including genomic profiling, bioinformatics and digital health solutions​.
North America benefits from a robust regulatory environment, particularly through organizations like the FDA (Food and Drug Administration) in the United States. The FDA has approved several personalized therapies such as CAR-T cell treatments such as Kymriah for leukemia and checkpoint inhibitors such as Keytruda for various cancers. These approvals drive market growth by providing a clear pathway for the development and commercialization of hyper personalized medicines​.
North America leads the adoption of advanced technologies like artificial intelligence (AI), which are pivotal in the development of personalized medicine. For instance, in October 2024, Ataraxis AI emerged from stealth with $4 million. The funding has enabled Ataraxis to develop groundbreaking AI-powered diagnostic tests that significantly enhance the prediction of patient outcomes and enable more precise, personalized treatments. The company also unveiled its first offering, Ataraxis Breast – the world’s first AI-native prognostic/predictive test for breast cancer and the most advanced clinically validated test available.
Asia-Pacific is growing at the fastest pace in the hyper personalized medicine market
The Asia-Pacific region is experiencing the fastest growth in the hyper personalized medicine market. The incidence of chronic diseases, such as cancer, diabetes and cardiovascular diseases, is rising in the Asia Pacific region. For instance, according to ScienceDirect, about 4,824,700 new cancer cases and 2,574,200 new cancer deaths occurred in China in 2022. Similarly, according to the National Institute of Health, it is predicted that by 2030 diabetes mellitus may afflict up to 79.4 million individuals in India, while China with 42.3 million. As chronic diseases become more prevalent, there is a greater need for targeted therapies, genomic diagnostics and personalized treatment approaches that are central to hyper personalized medicine.
The Asia Pacific region is increasingly adopting artificial intelligence (AI) to analyze patient data, enabling the creation of highly personalized treatment plans. Companies in countries like Japan, India and South Korea are integrating AI with genomic technologies to improve cancer diagnosis and treatment plans​.
For instance, in January 2024, GeneConnectRx, an innovative artificial intelligence (AI) platform launched by GenepoweRx, the diagnostic wing of the K&H clinic. This revolutionary step in personalized medicine marks a paradigm shift, empowering healthcare providers to customize treatments based on individual genetic makeup.
Competitive Landscape
The major global players in the hyper personalized medicine market are AstraZeneca PLC, GE HealthCare, Illumina, Inc., Novartis AG, Precision Biologics., Abbott Laboratories, ASURAGEN, INC., F. Hoffmann-La Roche Ltd., Achilles Therapeutics plc, QIAGEN N.V. and among others.
Report Insights
| Metrics | Details | |
| CAGR | 8.5% | |
| Market Size Available for Years | 2022-2032 | |
| Estimation Forecast Period | 2024-2031 | |
| Revenue Units | Value (US$ Bn) | |
| Segments Covered | Product Type | Therapeutics, Diagnostics, Software Solutions |
| Technology | Genomics, Proteomics, Bioinformatics, Artificial Intelligence (AI), Others | |
| Application | Oncology, Cardiology, Neurology, Immunology, Rare Disorders, Infectious Diseases, Others | |
| End-User | Hospitals, Specialty Clinics, Diagnostic Centers, Homecare Settings, Others | |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa | |
Why Purchase the Report?
- Pipeline & Innovations: Insights into clinical trials, product pipelines, and upcoming advancements.
- Market Positioning: Analysis of product performance and growth potential for optimized strategies.
- Real-World Evidence: Integration of patient feedback for enhanced product outcomes.
- Physician Preferences: Insights into healthcare provider behaviors and adoption strategies.
- Regulatory & Market Updates: Coverage of recent regulations, policies, and emerging technologies.
- Competitive Insights: Analysis of market share, competitor strategies, and new entrants.
- Pricing & Market Access: Review of pricing models, reimbursement trends, and access strategies.
- Market Expansion: Strategies for entering new markets and forming partnerships.
- Regional Opportunities: Identification of high-growth regions and investment prospects.
- Supply Chain Optimization: Assessment of risks and distribution strategies.
- Sustainability & Regulation: Focus on eco-friendly practices and regulatory changes.
- Post-Market Surveillance: Enhanced safety and access through post-market data.
- Value-Based Pricing: Insights into pharmacoeconomics and data-driven R&D decisions.
The global hyper personalized medicine market report delivers a detailed analysis with 70 key tables, more than 70 visually impactful figures, and 189 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2023
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.